Oramed Pharmaceuticals Future Growth
Future criteria checks 2/6
Oramed Pharmaceuticals's earnings are forecast to decline at 163% per annum while its annual revenue is expected to grow at 256.9% per year. EPS is expected to decline by 139.3% per annum.
Key information
-163.0%
Earnings growth rate
-139.3%
EPS growth rate
| Pharmaceuticals earnings growth | 21.5% |
| Revenue growth rate | 256.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 09 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 1 | -10 | N/A | N/A | 2 |
| 12/31/2024 | N/A | 10 | N/A | N/A | 2 |
| 9/30/2024 | N/A | 4 | -8 | -8 | N/A |
| 6/30/2024 | N/A | 21 | -2 | -2 | N/A |
| 3/31/2024 | 1 | 10 | -6 | -6 | N/A |
| 12/31/2023 | 1 | 6 | -11 | -10 | N/A |
| 9/30/2023 | 2 | -16 | -17 | -17 | N/A |
| 6/30/2023 | 3 | -20 | -19 | -18 | N/A |
| 3/31/2023 | 3 | -30 | -25 | -24 | N/A |
| 12/31/2022 | 3 | -37 | -28 | -28 | N/A |
| 9/30/2022 | 3 | -46 | -39 | -39 | N/A |
| 6/30/2022 | 3 | -46 | -43 | -43 | N/A |
| 3/31/2022 | 3 | -40 | -39 | -39 | N/A |
| 12/31/2021 | 3 | -35 | -33 | -33 | N/A |
| 11/30/2021 | 3 | -25 | -22 | -22 | N/A |
| 8/31/2021 | 3 | -22 | -22 | -21 | N/A |
| 5/31/2021 | 3 | -18 | -18 | -17 | N/A |
| 2/28/2021 | 3 | -15 | -16 | -15 | N/A |
| 12/31/2020 | 3 | -22 | -26 | -25 | N/A |
| 11/30/2020 | 3 | -15 | -16 | -16 | N/A |
| 8/31/2020 | 3 | -12 | -13 | -12 | N/A |
| 5/31/2020 | 3 | -11 | -13 | -13 | N/A |
| 2/29/2020 | 3 | -13 | -14 | -14 | N/A |
| 11/30/2019 | 3 | -13 | -12 | -12 | N/A |
| 8/31/2019 | 3 | -14 | -13 | -13 | N/A |
| 5/31/2019 | 3 | -15 | -14 | -14 | N/A |
| 2/28/2019 | 3 | -15 | -14 | -14 | N/A |
| 11/30/2018 | 3 | -14 | -16 | -16 | N/A |
| 8/31/2018 | 2 | -13 | N/A | -15 | N/A |
| 5/31/2018 | 2 | -12 | N/A | -12 | N/A |
| 2/28/2018 | 2 | -10 | N/A | -11 | N/A |
| 11/30/2017 | 2 | -10 | N/A | -10 | N/A |
| 8/31/2017 | 2 | -10 | N/A | -6 | N/A |
| 5/31/2017 | 2 | -13 | N/A | 3 | N/A |
| 2/28/2017 | 2 | -13 | N/A | 3 | N/A |
| 11/30/2016 | 1 | -11 | N/A | 8 | N/A |
| 8/31/2016 | 1 | -11 | N/A | 5 | N/A |
| 5/31/2016 | 0 | -8 | N/A | -3 | N/A |
| 2/29/2016 | 0 | -8 | N/A | -2 | N/A |
| 11/30/2015 | N/A | -8 | N/A | -6 | N/A |
| 8/31/2015 | N/A | -7 | N/A | -5 | N/A |
| 5/31/2015 | N/A | -7 | N/A | -5 | N/A |
| 2/28/2015 | N/A | -7 | N/A | -5 | N/A |
| 11/30/2014 | N/A | -6 | N/A | -5 | N/A |
| 8/31/2014 | N/A | -6 | N/A | -4 | N/A |
| 5/31/2014 | N/A | -5 | N/A | -4 | N/A |
| 2/28/2014 | N/A | -4 | N/A | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OJU1's earnings are forecast to decline over the next 3 years (-163% per year).
Earnings vs Market: OJU1's earnings are forecast to decline over the next 3 years (-163% per year).
High Growth Earnings: OJU1's earnings are forecast to decline over the next 3 years.
Revenue vs Market: OJU1's revenue (256.9% per year) is forecast to grow faster than the German market (5.7% per year).
High Growth Revenue: OJU1's revenue (256.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OJU1's Return on Equity is forecast to be high in 3 years time